Dr. Soley Bayraktar Verified by iCliniq

CREDENTIALS: Certifications - July 2012 American Academy of Procedural Medicine Nov 2011 American Board of Hematology and Oncology Aug 2008 American Board of Internal Medicine May 2010 American College of Physician Executives Dec 2004 ECFMG Active Licensures Aug 2010 Texas Medical Board Licensure (active) Feb 2010 Florida Medical Board Licensure (active) Oct 2018 Minnesota Medical Board Licensure (active) Jan 2019 Colorado Medical Board Licensure (active) May 2019 Connecticut Medical Board Licensure (active) May 2017 Wisconsin Medical Board Licensure (active) May 2019 Virginia Medical Board Licensure (active). HONORS, AWARDS, AND SERVICE: April 2011 ASCO Annual Meeting Merit Award July 2009 NIH Grant for AACR Molecular Biology in Clinical Oncology Workshop Jan 2006 Outstanding Academic Ambulatory Resident Award Wayne State University, School of Medicine, Detroit. MI ACADEMIC POSITIONS: 2019-present Professor, Department of Medicine, Division of Medical Oncology Biruni University School of Medicine, Istanbul, Turkey. 2014- 2018 Editorial Board Member, World Journal of Clinical Oncology 2016-2020 Editorial Board Member, Journal of Oncology and Hematology. 2017-2021 Editorial Board Member, Journal of Clinical Breast Cancer Research. PUBLICATIONS: Articles in Peer-Reviewed Journals 1. Bayraktar S, Gutierrez Barrera AM, Liu D, Valero V, Hunt K, Wu Y, Symmans F, Mehta K, Arun B. Tissue Transglutaminase 2 as a Predictive and Prognostic Factor: A Pilot Study of Neoadjuvant Therapy in Women with Breast Cancer. Integr Canc Biol Res 2017; 1:001. 2. Arun B, Bayraktar S, Shiang C, Qi Y, Wang B, et al. High Throughput siRNA Screen Identifies LRP8 as Druggable Metabolic Regulator in Triple-Negative Breast Cancer. SM Journal of Oncology and Hematology 2016, 1(1): 1003. 3. Bayraktar S, Qiu H, Liu D, Gutierrez-Barrera AM, Arun BK, Sahin AA. Histopathological Features of Non-neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer. Biomarkers in Cancer 2015;18(7):39-49. 4. Bayraktar S, Royce M, Stork-Sloots L, de Snoo F, Glück S. Molecular Subtyping Predicts Pathologic Tumor Response in Early-Stage Breast Cancer Treated with Neoadjuvant Docetaxel-Capecitabine +/-Trastuzumab Chemotherapy. Medical Oncol 2014;31(10):163. 5. Bayraktar S, Amendola L, Gutierrez-Barrera AM, Hashmi SS, Amos C, Gambello M, Ready KJ, Arun BK. Clinicopathologic Characteristics of Breast Cancer in BRCA-carriers and Non-carriers in Women 35 Years of Age or Less. The Breast. 2014;23(6):770-4. 6. Rocha-Lima CM, Marques Junior EQ, Bayraktar S, Broome P, Weissmann C, Nowacki M, Leslie M, Susnerwala S. A Multicenter Phase II Study of G17DT Immunogen Plus Irinotecan in Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan. Cancer Chemother Pharmacology 2014;74(3):479-86. 7. Bayraktar S, Jackson M, Gutierrez-Barrera AM, Liu D, Meric-Bernstam F, Brandt A, Woodson A, Litton J, Lu KH, Valero V, Banu K. Arun BK. Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers. Breast J. 2015;21(3):260-7. 8. Soares HP, Bayraktar S, Blaya M, Lopes G, Merchan J, Macintyre J, Mayo C, Green MR, Silva O, Levi J, Walker G, Rocha-Lima CM. A Phase II Study of Capecitabine Plus Docetaxel in Gemcitabine-pretreated Metastatic Pancreatic Cancer Patients: CapTere. Cancer Chemotherapy and Pharmacology 2014; 73(4):839-45. 9. Lossos C, Bayraktar S, Weinzierl E, Younes S, Hosein P, Posthumus J, DeAngelis L, Raizer J, Schiff D, Abrey L, Natkunam Y, Lossos I. LMO2, and BCL6 are Associated with Improved Survival in Primary Central Nervous System Lymphoma. Br J Haematol 2014;165(5):640-8. 10. Bayraktar U, Diaz LA, Ashlock B, Toomey N, Cabral L, Bayraktar S, Pereira D, Dittmer DP, Ramos JC. Zidovudine-Based Lytic-Inducing Chemotherapy for Epstein-Barr Virus-Related Lymphomas. Leukemia and Lymphoma 2014;55(4):786-94. 11. Bayraktar S, Thompson PA, Yoo SY, Do K, Sahin AA, Arun BK, Bondy ML, Brewster AM. The relationship between eight GWAS-identified single nucleotide polymorphisms and primary breast cancer outcomes. The Oncologist 2013; 18 (5):493-500. 12. Bayraktar S, Altundag K, Broglio K, Arun BK. Association between tumor characteristics and bone mineral density in postmenopausal breast cancer patients. The Breast Journal 2013; 19 (4):431-434. 13. Bayraktar S, Gutierrez Barrera AM, Lin E, Elsayegh N, Tasbas T, Litton J, Ibrahim NK, Morrow PK, Green M, Valero V, Booser DJ, Hortobagyi GN, Arun B. Outcome of Metastatic Breast Cancer in Selected Women with or without Deleterious BRCA Mutations. Clinical and Experimental Metastasis 2013; 30 (5):631-642. 14. Bayraktar S, Gutierrez-Barrera AM, Liu D, Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y, Symmans F, Arun BK. USP-11 as a Predictive and Prognostic Factor following Neoadjuvant Therapy in Women with Breast Cancer. Cancer J 2013; 19(1):10-7. 15. Rocha-Lima CM, Bayraktar S, Flores AM, MacIntyre J, Montero A, Baranda JC, Wallmark J, Portera C, Raja R, Stern H, Amler LC. Phase Ib Study of Drozitumab Combined with First-line MFOLFOX 6 plus Bevacizumab in Patients with Metastatic Colorectal Cancer. Cancer Investigation Journal 2012; 30(10):727-31. 16. Bayraktar S, Gutierrez Barrera AM, Lin E, Akar U, Litton J, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun B. Outcome of Triple Negative Breast Cancer in Patients with or without Deleterious BRCA Mutations. Breast Cancer Research and Treatment 2011; 130(1):145-53. 17. Bayraktar UD, Bayraktar S, Hosein P, Chen E, Koniaris LG, Rocha-Lima CM, Montero AJ. Preoperative Docetaxel/Cisplatin/5-Fluorouracil Chemotherapy in Patients with Locally Advanced Gastroesophageal Adenocarcinoma. Med Oncol 2012; 29(3):1707-10.2011. 18. Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Efficacy of Neoadjuvant Therapy with Trastuzumab Concurrent with Anthracycline- and Non-anthracycline-based Regimens for HER2-Positive Breast Cancer. Cancer 2012; 118(9):2385-2392. 19. Bayraktar S, Hernandez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN, Gonzalez-Angulo AM. Effect of Metformin on Survival Outcomes in Diabetic Patients with Triple Receptor–Negative Breast Cancer. Cancer 2012; 118 (5)2:1202-1211. 20. Arun B, Bayraktar S, Liu D, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton J, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin CT. Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA mutation carriers and non-carriers: a single institution experience. J Clin Oncol 2011; 29(28):3739-46. 21. Bayraktar S, Elsayegh N, Gutierrez Barrera AM, Lin H, Kuerer HM, Muse KI, Ready K, Litton J, Meric-Bernstam F, Hortobagyi GN, Albarracin CT, Arun B. Predictive Factors for BRCA1/2 Mutations in Women with Ductal Carcinoma In Situ. Cancer 2012; 118(6):1515-1522. 22. Rocha-Lima CM, Bayraktar S, Rubin EH, Poplin EA, Macintyre J, Flores AM, Merchan JR, Lucarelli AG, Schuck EL, Zojwalla NJ. A Phase I Trial of E7974 Administered on Day 1 of a 21-day Cycle in Patients with Advanced Solid Tumors. Cancer 2012; 1;118(17):4262-70. 23. Sahin K, Tuzcu M, Sahin N, Akdemir F, Ozercan I, Bayraktar S, Kucuk O. Inhibitory Effects of Combination of Lycopene and Genistein on 7,12- Dimethyl Benz(a)anthracene-Induced Breast Cancer in Rats. Nutr and Cancer 2011; 63(8):1279-86. 24. Bayraktar UD, Chen E, Bayraktar S, Ku N, Herna S, Montero A, Rocha-Lima CM. Does Delay of Adjuvant Chemotherapy Affect the Clinical Outcome in Colon Cancer? Cancer 2011; 117 (11):2364-2370. 25. Bayraktar S, Bayraktar UD, Stefanovic A, Lossos I. Primary Ocular Adnexal MALT Lymphoma: a single-institution experience in a large cohort of patients. Br J Haematol 2010; 152(1):72-80. 26. Bayraktar S, Bayraktar UD, Stefanovic A, Lossos I. Primary CNS Lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. J Neurooncol 2011; 101(2):257-65. 27. Bayraktar S, Stefanovic A, Montague N, Davis J, Murray T, Lossos I. Central Nervous System Manifestations of Marginal Zone B-cell Lymphoma. Ann Hematol 2010; 89(10):1003-09. 28. Tuzcu M, Sahin N, Ozercan I, Seren S, Sahin K, Kucuk O. The effects of selenium supplementation on the spontaneously occurring fibroid tumors of the oviduct, 8-hydroxy-2'-deoxyguanosine levels, and heat shock protein 70 response in Japanese quail. Nutr Cancer 2010; 62(4):495-500. 29. Sahin K, Akdemir F, Tuzcu M, Sahin N, Onderci M, Ozercan R, Ilhan N, Kilic E, Seren S, Kucuk O. Genistein suppresses spontaneous oviduct tumorigenesis in quail. Nutr Cancer 2009; 61(6):799-806. 30. Ozercan I, Sahin N, Akdemir F, Orhan F, Onderci M, Sahin K, Seren S, Kucuk O. Chemoprevention of Fibroid Tumors by Epigallocatechin-3-gallate (EGCG) in Quail. Nutr Res 2008; 28(2): 92-7. 31. Sahin K, Ozercan R, Onderci M, Sahin N, Khachik F, Seren S, Kucuk O. Dietary Tomato Powder Supplementation in the Prevention of Leiomyoma of the Oviduct in the Japanese Quail. Nutr Cancer 2007; 59(1):70-5. 32. Vaishampayan U, Hussain M, Banerjee M, Seren S, Sarkar F, Fontana J, Forman J, Cher M, Powell I, Pontes E, Kucuk O. Lycopene and Soy Isoflavones in the Treatment of Prostate Cancer. Nutr Cancer 2007; 59(1):1-7. Book Chapters 1. Bayraktar S, Arun B. Breast Cancer in Young Women, Chapter: Establishing a Program for Young Women at High Risk for Breast Cancer. Springer, Switzerland, 2018 (in press). 2. Bayraktar S, Aydiner A. Breast Cancer: A Guide to Clinical Practice, Chapter: Adjuvant Therapy for Her2-positive Early-Stage Breast Cancer. Springer, Switzerland, 2019, pages 383-411. 3. Bayraktar S, Aydiner A. Breast Cancer: A Guide to Clinical Practice, Chapter: Treatment of Her2-negative Metastatic Breast Cancer. Springer, Switzerland, 2019, pages 483-508. 4. Bayraktar S. Breast Disease: Management and Therapies, Chapter: Immunotherapy in Breast Cancer. Springer, Switzerland, 2019 (in press). 5. Bayraktar S. Breast Disease: Management and Therapies, Chapter: Breast Cancer in Older Women. Springer, Switzerland, 2019 (in press). 6. Aydiner A, Bayraktar S, Sen F et al. Breast Disease: Management and Therapies, Chapter: A Review of Local and Systemic Therapy in Breast Cancer. Springer, Switzerland, 2019 (in press). 7. Bayraktar S, Arun B. Managing BRCA mutation carriers: Medical Management of Breast Cancer in BRCA Mutation Carriers. Springer, Switzerland 2017 (Anees Chagpar, Editor), Vol.1, p.135-150. 8. Bayraktar S, Arun B. Breast Disease: Diagnosis and Pathology, Chapter: Epidemiology, Risk Factors, and Prevention. Springer, Switzerland 2015. Vol. 1, p. 57-87 31. 9. Heath E, Seren S, Sahin K, Kucuk O. Tomatoes, Lycopene, and Human Health: Preventing chronic diseases, Chapter: The Role of Tomato Lycopene in the Treatment of Prostate Cancer (Venkat Rao, Editor). Caledonian Press, Barcelona, Spain, 2006. 10. Kittaneh M, Bayraktar S, Montero A, MD, Snoo F, Glück S. Molecular profiling for breast cancer, and Its Impact on Therapeutic Decisions. Cancer de Mama. Avances y Controversias. Editorial Alfil, San Rafael, Mexico, 2015. ISBN 978-607-741-134-5. Review Articles 1. Bayraktar S, Gluck S, Darling HS. Update on PARP inhibitor therapy for solid tumors. Journal of Cancer Prevention and Current Research 2019;10(4):98‒107. 2. Bayraktar S, Batoo S, Okuno S, Gluck S. Immunotherapy in Breast Cancer. Journal of Carcinogenesis 2019;18:2. 3. Batoo S, Bayraktar S, Okuno S, Gluck S. Recent Advances in the Treatment of Her2-positive Early-Stage Breast Cancer. Journal of Carcinogenesis 2019;24:2. 4. Bayraktar S, Arun B. BRCA Mutation Genetic Testing Implications in the USA. The Breast 2017;31:224-232. 5. Bayraktar S, Rocha-Lima C. Molecularly Targeted Therapies for Advanced or Metastatic Non-Small-Cell Lung Carcinoma. World Journal of Clinical Oncology 2013; 4(2): 29-42. 6. Bayraktar S, Arun B, Gluck S. DCIS: How should we treat it? Breast Cancer Management 2013; 2(3):245-256. 7. Bayraktar S, Gluck S. Molecularly Targeted Therapies for Metastatic Triple-negative Breast Cancer. Breast Cancer Research and Treatment 2013; 138(1):21-35. 8. Bayraktar S, Rocha-Lima CM. Emerging Cell Cycle Inhibitors for Pancreatic Cancer. Expert Opinion on Emerging Drugs 2012; 17(4):571-82. 9. Bayraktar S, Gluck S. Systemic Therapy Options in BRCA Mutation-associated Breast Cancer. Breast Cancer Research and Treatment 2012; 135(2):355-66. 10. Bayraktar S, Gluck S. Management of Women with BRCA1/2-mutation Associated Breast Cancer. Breast Cancer Management 2012; 1(2):157–164. 11. Bayraktar S, Gluck S. Management of Capecitabine-related Gastrointestinal Toxicities in Women with Breast Cancer. Commun Oncol 2011; 8(2):81-87. 12. Bayraktar S, Arun B. Dose-dense Chemotherapy in Breast Cancer. The Breast Journal 2011; 18(3):261-266. 13. Bayraktar S, Rocha-Lima C. Advanced and Metastatic Pancreatic Cancer: Molecular Targeted Therapies. Mount Sinai J of Med 2010; 77(6):606-19. 14. Bayraktar S, Bayraktar UD, Rocha-Lima C. Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol 2010; 16(6):673-682. 15. Bayraktar S, Escalon M. Secondary Hematological Malignancies Following Breast Cancer Treatment. Oncology Reviews 2010; 4(1):51-59. 16. Bayraktar UD, Bayraktar S, Rocha-Lima C. Molecular Basis and Management of Gastrointestinal Stromal Tumors. World J Gastroenterol 2010; 16(22):2726-34. 17. Bayraktar UD, Bayraktar S. The Treatment of Iron-deficiency Anemia Associated with Gastrointestinal Tract Diseases. World J Gastroenterol 2010; 16(22):2720-25. 18. Gullett NP, Ruhul Amin AR, Bayraktar S, Pezzuto JM, Shin DM, Khuri FR, Aggarwal BB, Surh YJ, Kucuk O. Cancer prevention with natural compounds. Semin Oncol 2010; 37(3):258-81. 19. Bayraktar S, Bayraktar UD, Rocha-Lima C. Timing of Adjuvant and Neoadjuvant Therapy in Colorectal Cancer. Clin Colorectal Cancer 2010;9(3):144-149. 20. Bayraktar S, Wahab M. Current Medical and Surgical Options for Androgen Deprivation in Prostate Cancer Patients. Open Prostate Journal 2010; 3:39-46. 21. Bayraktar S, Wahab M. The Mechanism of Androgen Deprivation and the Androgen Receptor. Open Prostate Journal 2010; 3:47-56. 22. Seren S, Mutchnick M, Hutchinson D, Harmanci O, Bayraktar Y, Kucuk O. Potential Role of Lycopene in the Treatment of Hepatitis C and Prevention of Hepatocellular Carcinoma. Nutr Cancer 2008; 60(6):729-765. 23. Seren S, Lieberman R, Bayraktar UD, Heath E, Sahin K, Kucuk O. Lycopene in Cancer Prevention and Treatment. Am J Therapeutics 2008; 15(1):66-81. 24. Bayraktar UD, Seren S, Bayraktar Y. Hepatic Venous Outflow Obstruction: Three Similar Syndromes. World J Gastroenterol 2007; 13(13):1912-27. 25. Heath E, Sahin K, Seren S, Kucuk O. Lycopene: Prospects for Chemoprevention and Treatment of Prostate Cancer. Perspectives in Agriculture, Veterinary Science, Nutrition and Natural Resources 2006; 1: No: 064. Case Reports: 1. Bayraktar S, Bernal E, Lian E. Concurrent Thrombotic Thrombocytopenic Purpura and Immune Thrombocytopenic Purpura in a Patient with Metastatic Neuroendocrine Tumor Successfully Treated with Rituximab-CVP. BMJ case reports 2010; doi:10.1136/bcr.07.2010.3144. 2. Bayraktar S, Escalon M. Successful Pregnancy in a Patient with Chronic Myelogenous Leukemia exposed to Dasatinib during the First Trimester. Accepted for publication at BMJ Case Reports 2010; doi:10.1136/bcr.05.2010.2975. 3. Bayraktar S, Gluck S. Surviving Metastatic Breast Cancer for 18 Years: a case report and literature review. The Breast Journal 2011; 17(5):521-524. 4. Bayraktar S, Bassini W, Goodman M. Primary Pituitary Lymphoma: A Case Report and Literature Review. Acta Haematol 2010; 123(2):121-125. 5. Bayraktar S, Goodman M. Detection of BCR-ABL positive cells in an asymptomatic patient: A Case Report and Literature Review. Case Report Med 2010:939706. 6. Bayraktar UD, Dufresne A, Bayraktar S, Purcell RR. Esophageal Cancer Presenting with Atrial Fibrillation. J Med Case Reports 2008; 2:292-95. 7. Perez N, Maryvale S, Seren S, Feng J, Pansare V, Dhar R. Metastatic Prostate Cancer Presenting as Mediastinal Lymphadenopathy Identified by Endoscopic Ultrasound with Fine Needle Aspiration. Gastrointest Endosc 2007; 65(6):948-49. Abstracts: 1. Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Efficacy of Neoadjuvant Therapy with Trastuzumab Concurrent with Anthracycline- and Non-anthracycline-based Regimens for HER2-Positive Breast Cancer. 47th ASCO Annual Meeting, J Clin Oncol, 2011 (suppl; Abstr 532). 2. Bayraktar S, Thompson PA, Yoo SY, Do K, Sahin AA, Arun BK, Bondy ML, Brewster AM. Prognostic Relevance of Eight Genome-Wide Association Studies-identified Single-nucleotide Polymorphisms in Primary Breast Cancer. AACR International Conference on Frontiers in Cancer Prevention Research, AACR Cancer Prevention Research 2011; 4 (10), (suppl 1; Abstr A61). 3. Elsayegh N, Bayraktar S, Gutierrez Barrera AM, Lin H, Kuerer HM, Muse KI, Ready K, Litton J, Meric-Bernstam F, Hortobagyi GN, Arun B. Prevalence of BRCA1 and BRCA2 Mutations in Women with Diagnosed with DCIS. 47th ASCO Annual Meeting, J Clin Oncol, 2011 (suppl; Abstr 1512). 4. Bayraktar S, Bayraktar UD, Stefanovic A, Lossos I. Primary CNS lymphoma in HIV positive and negative patients: Comparison of clinical characteristics, outcome and prognostic factors. 46th ASCO Annual Meeting, J Clin Oncol 28, 2010 (suppl; Abstr e12502). 5. Bayraktar UD, Bayraktar S, Ku N, Herna S, Marchetti F, Sands L, Jones C, Montero A, Rocha Lima C. Does the delay of adjuvant chemotherapy affect the clinical outcome in colon cancer? 45th ASCO Annual Meeting, J Clin Oncol 27:15s, 2009 (suppl; Abstr 4046). 6. Bayraktar S, Bayraktar UD, Pegram M, Hurley J. Neoadjuvant dose-dense docetaxel, carbo platinum, and trastuzumab (ddTCH) chemotherapy for HER-2 over-expressing breast cancer. 45th ASCO Annual Meeting, J Clin Oncol 27 (15), 2009 (suppl; Abstr e11557). 7. Bayraktar UD, Ochoa R, Bayraktar S, Matsangou M, Ramos JC. High-dose Methotrexate and Zidovudine in Combination with Alternating DA-EPOCH is an Effective Regimen for the Treatment of EBV Related Plasmablastic Lymphoma. ASH Annual Meeting. Blood 2009; 114: 4753. 8. Seren S, Bayraktar UD, Ehrinpreis MN. Esophageal pH monitoring with Bravo (TM) capsule in patients with suspected gastroesophageal reflux disease. 72nd Annual Meeting of the American-College-of-Gastroenterology, Am J Gastroenterol 2007; 102:S130: A33. 9. Atasi B, Seren S, Guzman J. Overuse of Stress Ulcer Prophylaxis in Hospitalized Internal Medicine Patients. Digestive Disease Week Meeting, Washington, DC, Gastroenterology 2007; 132(4): A644. 10. Atasi B, Godbold H, Moodie K, Shawesh L, Seren S, Guzman J. Stress ulcer prophylaxis for the acutely-ill patient: What do residents know? 72nd Annual Scientific Meeting of the American-College-of-Gastroenterology, Philadelphia, PA, Oct 2007. Amer J Gastroenterol 2007; 102: S430:A847. 11. Perez N, Maryvale S, Seren S, Feng J, Pansare V, Dhar R. Metastatic Prostate Cancer Presenting as Mediastinal Lymphadenopathy Identified by Endoscopic Ultrasound with Fine Needle Aspiration. 71st Annual Scientific Meeting of the American-College-of-Gastroenterology, Am J Gastroenterol 2006;101 (9): S222-S39:A566 Presentations at National or International Conferences: 1. Bayraktar S. BIT’s 10th Annual World Cancer Congress. Session 403: BRCA Mutation Genetic Testing Implications in the United States, Barcelona, Spain, May 2017. 2. Bayraktar S. Memorial Antalya Hospital. Management in BRCA-positive Women with Breast Cancer, İstanbul, Turkey, April 2016. 3. Bayraktar S. Beşiktaş Akatlar Cultural Center. Women Cancer Awareness Symposium, İstanbul, Turkey, March 2016. 4. Bayraktar S. Bahçelievler Physical Rehabilitation Hospital. Cancer Screening Education Program, İstanbul, Turkey, February 2016. 5. Bayraktar S. Haydarpaşa Numune Hospital. Management in healthy BRCA-positive Individuals, İstanbul, Turkey, February 2016. 6. Bayraktar S. Breast Cancer Awareness. Şişli Kent Cultural Center. 3rd Annual Breast Cancer Awareness Symposium, İstanbul, Turkey, October 2015. 7. Bayraktar S. Advances in the Management of BRCA-associated Breast Cancers. 4th Annual Medical Oncology Symposium, Antalya, Turkey, March 2012. 8. Bayraktar S, Thompson PA, Yoo SY, Do K, Sahin AA, Arun BK, Bondy ML, Brewster AM. Prognostic Relevance of Eight Genome-Wide Association Studies-identified Single-nucleotide Polymorphisms in Primary Breast Cancer. AACR Frontiers in Cancer Prevention Research Meeting, Boston, MA, Oct 2011. 9. Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Efficacy of Neoadjuvant Therapy with Trastuzumab Concurrent with Anthracycline- and Non-anthracycline-based Regimens for HER2-Positive Breast Cancer. Poster Discussion Session: Breast Cancer - HER2/ER, 2011 ASCO Annual Meeting, Chicago, IL, June 2011. 10. Elsayegh N, Bayraktar S, Gutierrez Barrera AM, Lin H, Kuerer HM, Muse KI, Ready K, Litton J, Meric-Bernstam F, Hortobagyi GN, Arun B. Prevalence of BRCA1 and BRCA2 Mutations in Women with Diagnosed with DCIS. 2011 ASCO Annual Meeting, Chicago, IL, June 2011. 11. Seren S, Perez N, Maryvale S. Metastatic Prostate Cancer Presenting as Mediastinal Lymphadenopathy Identified by Endoscopic Ultrasound with Fine Needle Aspiration. The ACG Annual Scientific Meeting and Postgraduate Course, Las Vegas, NV, Oct 2006. 12. Seren S, Bayraktar UD, Ehrinpreis MN. Characteristics of patients with reflux esophagitis, non-erosive reflux disease, and functional heartburn. 72nd Annual Meeting of the American-College-of-Gastroenterology (ACG), Philadelphia, PA, Oct 2007. PROFESSIONAL MEMBERSHIPS 2012- present American Turkish Medical Society 2012- present Turkish American Medical Association 2010 – present American College of Physician Executives (ACPE) 2009 – present American Association for Cancer Research (AACR) 2008 – present American Society of Oncology (ASCO) Dr. Bayraktar received the Outstanding Academic Ambulatory Resident Award while an internal medicine resident in 2006. As a fellow, she received the NIH Grant for AACR Molecular Biology in Clinical Oncology and ASCO Annual Meeting Merit Award. In 2012, she received a physician executive award from the University of Massachusetts.